Search
NasoVAX
go.drugbank.com/drugs/DB15859InvestigationalAs of June 2020, NasoVAX is being evaluated in a Phase 2 clinical trial for safety and effectivness in preventing worsening symptoms in hospitalized COVID-19 patients (NCT04442230). … The compound has already shown to be tolerated with no adverse effects or fever in healthy individuals with a nearly 6-fold cellular immune response in comparison to an injectable vaccine[L16313].
IP501
go.drugbank.com/drugs/DB06450ExperimentalIP-501 is an investigational antifibrotic compound being tested for the treatment of alcohol-induced liver disease and chronic hepatitis-C-induced cirrhosis.
XP12B
go.drugbank.com/drugs/DB04928InvestigationalIt was granted Fast Track status for this indication by the FDA in November 2004.
Arbaclofen
go.drugbank.com/drugs/DB08891InvestigationalIt is believed to be a selective gamma-amino butyric acid type B receptor agonist, and has been investigated as a treatment for autism spectrum disorder and fragile X syndrome in randomized, double blind
Pralnacasan
go.drugbank.com/drugs/DB04875ExperimentalPralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).
Mepartricin
go.drugbank.com/drugs/DB13633InvestigationalCategories: Drugs Used in Benign Prostatic HypertrophyZeranol
go.drugbank.com/drugs/DB11478ExperimentalVet approvedIt is a mycotoxin, derived from fungi in the Fusarium family, and may be found as a contaminant in fungus-infected crops. … It is 3-4x more potent as an estrogen agonist than the related compound zearalenone.
Prolectin-M
go.drugbank.com/drugs/DB16521Investigational[L31343] It is being investigated in the clinical trial NCT04512027 (Prolectin-M in COVID-19 Patients Having Mild to Moderate Symptoms Not Requiring Oxygen Support. (Prolectin-M)). … Prolectin-M is a (1-6)-alpha-D-mannopyranose[L31338] and acts as an antagonist of galectin.
AVI-7537
go.drugbank.com/drugs/DB15433Investigational[L46207] AVI-7537 is under investigation in clinical trial NCT01593072 (A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7537 in Healthy Adult Volunteers). … AVI-7537 is an antisense molecule that binds to the Ebola virus mRNA to prevent the viral replication.
Human growth hormone-releasing peptide 3
go.drugbank.com/drugs/DB19227InvestigationalHuman growth hormone-releasing peptide 3 is under investigation in clinical trial NCT00846872 (Effect of Continuous GHRP-3 Infusion at on GH-IGF-I System, Blood Pressure, Glucose, and Insulin Resistance